Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5072)	12/6/2001 10:04:14 AM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

I haven't followed HGSI closely, but have noticed its recent downtrend. Might that be related to the info to be discussed Friday???? Human Genome (HGSI) 38.63: Plans to sponsor a conference call for analysts and investors to discuss clinical trial data on repifermin. The call will begin at 5 p.m Eastern on Friday.

To: scaram(o)uche who wrote (5072)	12/6/2001 10:07:38 AM
From: Biomaven	Respond to of 52153

Well this Prudent Bear "performance" chart is very amusing: prudentbear.com Hey - I wonder what our "performance" looks like for periods when the market was only going up? <g> For some reason Tice went after biotechs at one point instead of focusing on the dot.com disaster. Don't know what he's been short more recently. OTOH, satisfying as it feels, it's not always a good thing when the shorts are routed. Part of what enabled the biotech bubble in 2000 was the fact that all the shorts were long gone from the field. Peter